Acceleron's long-running collaboration with Celgene on sotatercept has taken another turn, with an amendment of their agreement to give Acceleron the …
Acceleron takes back drug rights from Celgene to start pulmonary pushRead More
September 21, 2017 by abzali123
Acceleron's long-running collaboration with Celgene on sotatercept has taken another turn, with an amendment of their agreement to give Acceleron the …
Acceleron takes back drug rights from Celgene to start pulmonary pushRead More
September 21, 2017 by abzali123
Sypromics have announced a new research partnership with Solid Biosciences. Under the terms of the agreement, Synpromics will provide Solid …
Synpromics announces Gene Therapy research partnership with Solid BiosciencesRead More
September 19, 2017 by abzali123
Newly diagnosed families Newly diagnosed families …
September 19, 2017 by abzali123
PerkinElmer have announced a collaboration with In-Depth Genomics (IDG) to support IDG's Whole Genome Sequencing (WGS) Diagnostic Program that will …
September 19, 2017 by abzali123
This afternoon, Action Duchenne has since had confirmation by the Santhera team and this article that this decision has no consequences on their …
Update on CHMP negative opinion for Raxone (idebenone)Read More
September 18, 2017 by abzali123
Phrixus Pharmaceuticals has announced that the first person living with Duchenne has completed 15 months of treatment with Carmeseal-MD. The …
First person reaches 15 month mark through Phrixus’ Carmseal-MDRead More
September 12, 2017 by abzali123
Promising microdystrophin pre-clinical work, moving towards a potential therapy has shown to restore muscle function in the canine model (dogs). …
September 12, 2017 by abzali123
Parallel London 2017 was an absolutely inspirational day! 60 incredible people took part for Action Duchenne, representing the entire community, …
September 12, 2017 by abzali123
Biophytis clinical stage drug-candidate Sarconeos demonstrates efficacy in preclinical models of Duchenne muscular dystrophy An abstract …
Sarconeos announced as new potential treatment for DuchenneRead More
September 11, 2017 by abzali123
We are delighted to announce the first people are enrolled in the UK's Early Access to Medicines Scheme (EAMS) for Raxone. Janet Bloor, Chair of …
Breaking news – first people enrolled in Raxone EAMS scheme in UKRead More
September 7, 2017 by abzali123
Kathy Wedell, mother to Isaac, is Action Duchenne's new Campaigns Officer "On World Duchenne Awareness Day I’m delighted to announce that …
Action Duchenne are Delighted to Announce Our New Campaigns Officer: KathyRead More
August 24, 2017 by abzali123
On Friday 10 November 2017, the first day of our new and extended international conference will be dedicated to new horizons in pre-clinical research …
Action Duchenne
Wellesley House
Duke of Wellington Avenue Royal Arsenal
London
SE18 6SS
07535 498 506
info@actionduchenne.org